Results: 16

Osteonecrosis múltiple inducida por glucocorticoides

La osteonecrosis múltiple es una entidad poco frecuente que se define por el compromiso de al menos tres regiones diferentes. Es indispensable el abordaje multidisciplinario de los pacientes que la padecen tanto para el diagnóstico como el tratamiento oportuno. Presentamos el caso clínico de un pacien...

Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals

An. bras. dermatol; 96 (4), 2021

Effect of topical corticosteroids on nasal patency after acute positive airway pressure exposure

Abstract Introduction Nasal congestion and obstruction are reported in the majority of continuous positive airway pressure users and are frequently cited as reasons for noncompliance. Baseline inflammation due to allergic rhinitis could increase or exacerbate the inflammatory effect of high airflow in t...

Tratamento da asma: o que podemos aprender com um médico do século XVI

Girolamo Cardano, médico italiano do Renascimento, descreveu em suas memórias o tratamento detalhado de um arcebispo escocês que apresentava, havia mais de 10 anos, um quadro de asma grave. O tratamento, sem paralelo na história da Medicina até então, foi um verdadeiro sucesso, ajudando a firmar o ...

Individualized treatment for allergic rhinitis based on key nasal clinical manifestations combined with histamine and leukotriene D4 levels

Abstract Introduction The types of allergic rhinitis are roughly classified based on the causative antigens, disease types, predilection time, and symptom severity. Objective To examine the clinical typing and individualized treatment approach for allergic rhinitis and to determine the optimal treatmen...

Incapacitating solar urticaria: successful treatment with omalizumab

An. bras. dermatol; 94 (3), 2019
Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontan...

Consensus on the diagnostic and therapeutic management of chronic spontaneous urticaria in adults - Brazilian Society of Dermatology

An. bras. dermatol; 94 (2,supl.1), 2019
Abstract: Background: Urticarias are frequent diseases, with 15% to 20% of the population presenting at least one acute episode in their lifetime. Urticaria are classified in acute ( ≤ 6 weeks) or chronic (> 6 weeks). They may be induced or spontaneous. Objectives: To verify the diagnostic and...

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis

J. bras. pneumol; 44 (5), 2018

Urticaria and angioedema as possible reactions of omalizumab

An. bras. dermatol; 93 (2), 2018